TORONTO, Aug. 07, 2020 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that it will host a webinar on August 18, 2020 at 11:00am EST to present an overview of the LSALT Peptide development program and upcoming Phase II human trial to treat inflammation in patients with severe complications from Covid-19.

TORONTO, Aug. 04, 2020 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that it received independent Institutional Review Board (IRB) approval for the Phase II trial of its lead drug LSALT peptide (Metablok) targeting acute lung injury and acute kidney injury caused by inflammation in patients with severe cases of COVID-19.

TORONTO, July 28, 2020 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates for treating organ damage caused by inflammation, today announced that it has chosen its first U.S. clinical site for the Phase II trial of its lead drug LSALT peptide (Metablok).